Wave Life Sciences Ltd. (nasdaq: WVE) has announced that its president and Chief Executive Officer, Paul Bolno, MD, MBA, is scheduled to participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 4:55 p.m. ET.

According to the announcement, a live webcast of the presentation can be accessed via the “Investor Events” section of the company’s website. A replay will be archived on the site for a limited time following the event.

Wave Life Sciences Focus on RNA Medicines

Wave’s RNA medicines platform, PRISM^®combines multiple modalities, chemistry innovation and deep insights in human genetics.

wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company’s RNA medicines platform, PRISM^®, combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders.

Wave Life Sciences’ toolkit of RNA-targeting modalities includes editing, splicing, RNA interference, and antisense silencing, providing the company with capabilities for designing and delivering candidates that address disease biology. The company’s pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit.

Advancing RNA Therapeutics

Driven by the calling to “Reimagine Possible”, Wave is headquartered in Cambridge, MA. The company is focused on advancing RNA therapeutics to treat a range of diseases.